FarmantraFarmantraFarmantraFarmantra
Menu
  • Home
  • About Us
  • Team
  • Services
    • Valuation
      • Valuation by real options
    • Strategic CFO Services
    • Capital Raising
  • Case Study
  • News & Blog
    • News
    • Blog
  • Contact

Posts Categorized: Blog

  • Home
  • Blog
  • ( - Page 4)

Blog

Value creation in life sciences – 2

In this video we discuss what happens when price exceeds value. Can the market sustain it? What would be the consequence if all companies raising money talk about the big market potential leading to market delusion. So if you are…

Continue Reading...

Blog

Value creation in life sciences – 1

In this video, we talk about the differences between value and price. Why an investor would invest at your pre money valuation

Continue Reading...
blog-defecto

Blog

Are developing countries an opportunity for Spanish companies to emerge from...

The casual answer to this question seems obvious, we would say “Yes”. Markets in these countries offer very favourable growth, usually double-digit, and their populations are several times larger than that of countries within the EU. Consider, for example, a…

Continue Reading...
blog-defecto

Blog

The Valuation Dilemma: VCs vs Pharmaceutical Companies

I had an interesting discussion with one of the biotech entrepreneurs last week. He was curious to see that when he discusses the value of his product with the VCs, he gets a very different value. On the other hand…

Continue Reading...
blog-defecto

Blog

¿Son los países emergentes una oportunidad para que las empresas españolas...

La respuesta ”a bote pronto” a esta pregunta parece evidente, diríamos que Sí. Los mercados en estos  paises ofrecen crecimientos muy importantes, normalmente de doble digito, siendo  sus poblaciones varias veces superiores a la de paises de la EU, por…

Continue Reading...
blog-defecto

Blog

Oh! these risk premiums for emerging markets!!!

These were the exact words from the management of a biotech company based in an emerging market when we were negotiating a deal with them. The company was supposed to in license the product, develop it and launch in its…

Continue Reading...
blog-defecto

Blog

¿Son los países emergentes una oportunidad para que las empresas españolas...

La respuesta ”a bote pronto” a esta pregunta parece evidente, dir?amos que S?. Los mercados en estos  pa?ses ofrecen crecimientos muy importantes, normalmente de doble d?gito, siendo  sus poblaciones varias veces superiores a la de pa?ses de la EU, por…

Continue Reading...
blog-defecto

Blog

Who are the marginal investors in your company?

Risk is an integral part of valuation. When we try to value a company or equity, we use the cost of capital or the cost of equity as the discount rate. For equity investors, the cost of equity is the…

Continue Reading...
blog-defecto

Blog

Does the future look bright for India´s Vaccine Industry?

Following the Wold Health Organisation?s approval of India?s vaccine regulatory system two weeks ago there has been much speculation over what the future holds for India?s Vaccine Industry. By achieving WHO approval the Industry has reached an important milestone that projects a bright…

Continue Reading...
blog-defecto

Blog

Should you use your borrowing rate as the cost of debt?

The company ABC borrowed 50 M USD at 2% interest rate 3 years ago. What should be the cost of debt in calculating the cost of capital of the company? Should you use 2% as the cost of debt as…

Continue Reading...
  • ←
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • →

Categories

  • Blog
  • News

Reach Us

Passeig d’Amunt 7, bajos Barcelona 08024 SPAIN
  • Phone: +34 933154869
  • Email: info@farmantra.com

Others sections

  • Legal
  • Privacy Policy
  • Cookies
  • Contact

© Farmantra, All Rights Reserved. Diseño web Espiral Group